Affibody is a private clinical-stage Swedish biotech company focused on developing into an integrated biopharma company utilizing next generation biotherapeutics based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.
The company operates a focused experimental medicine model and currently has three clinical stage programs. The first two are therapeutic programs that target psoriasis and rare Immunoglobulin G (IgG)-mediated autoimmune diseases. The third program is a diagnostic imaging program that is directed primarily towards metastatic breast cancer.
In addition, to its portfolio of innovative drug projects the company offers the half-life extension technology, Albumod™, for outlicensing.
New therapeutic options providing a long-term benefit or even a cure are needed for effective cancer treatment, while also reducing severe side effects. Affimed aims to address these challenges by redirecting immune cells with multi-specific antibodies to achieve optimized killing of malignant cells.
Leveraging our modular and versatile ROCK® (Redirected Optimized Cell Killing) platform, we generate proprietary, next-generation bispecific antibodies. Our tetravalent (four binding sites) bispecific (two targets) immune cell engagers have the ability to bring NK cells or T cells into proximity to cancer cells and trigger a signal cascade that leads to the destruction these cancer cells.
A number of clinical and preclinical programs are in development based on the ROCK® platform and our tetravalent bispecific immune cell engagers have already shown a favorable safety profile and promising signs of therapeutic efficacy.
We believe that our product candidates, alone or in combination with other agents (e.g. checkpoint modulators, adoptive NK cells or cytokines), may ultimately improve clinical outcomes in cancer patients and could eventually become a key element of modern targeted oncology care.
Affimed was founded in 2000 based on technology developed by the group led by Professor Melvyn Little at Deutsches Krebsforschungszentrum, the German Cancer Research Center, or DKFZ, in Heidelberg. In 2009, Affimed set up its wholly owned unit AbCheck in Pilsen, Czech Republic, which focuses on fully human antibody screening and optimization.
Anagenesis is a preclinical‐stage stem cell-based company focused on developing novel treatments for genetic and age-related muscle degenerative diseases with unmet medical needs.
A wide spectrum of diseases in which specific tissues are lost or damaged remain incurable. This reflects a lack of drugs to promote regeneration or of transplantable cells to replace those that are missing. One example of this urgent unmet need are the human conditions that lead to degeneration of skeletal muscle, ranging from muscular dystrophies and neuromuscular disease to muscle-wasting caused by disuse. However, to date, it has not been possible to generate muscle cells in sufficient quantity for high-throughput drug screening, or sufficient purity for cell-based therapy.
Patented new technologies licensed-in by Anagenesis have changed all this. Using stem cells as a renewable source, Anagenesis scientists first generated the natural embryonic precursors of skeletal muscle then devised protocols for turning the precursors into contractile muscle fibers in the culture dish. The resulting muscle cells are purer and more abundant than any before and successfully colonize damaged muscle when transplanted in vivo. Moreover, when stem cells from mice with muscle disorders are used, the resulting muscle fibers show characteristic disease-related defects in culture. The time is therefore ripe for drug screening to enhance muscle regeneration and/or correct disease phenotypes, and for a reasoned approach to therapeutic muscle reconstruction.
Anagenesis has exclusive rights to two key patents from the French national biomedical research agency INSERM. Two main activities will generate revenues: a) Cell therapy for genetic muscle disorders b) Cell-based screening of small molecules
Anagenesis already secured its first private funding from the AFM (French muscular dystrophy association) to develop applications in the skeletal muscle therapeutic area. http://anagenesis-biotech.com/
Anima Biotech, Inc.
Anima Biotech is advancing Translation Control Therapeutics, the first and only platform for the discovery of small molecule drugs that specifically control mRNA translation as a new strategy against hard and undruggable targets in many diseases.
Anima’s proprietary technology enables visualization and monitoring of target protein translation via pulses of light emitted by ribosomes. The fully automated high-throughput screening system discovers small molecules that modulate the light, as they decrease or increase the target protein’s production. The platform integrates proprietary technologies in biology, bioinformatics, image analysis, big data analysis and artificial intelligence algorithms in a cloud computing software architecture.
Anima is developing an internal pipeline across multiple therapeutic areas with high unmet need and hard targets. Current programs are in Fibrosis (inhibiting the synthesis of Collagen type I), Viral infections (Respiratory Syncytial Virus – interfering with viral protein synthesis), Oncology (C-Myc translation inhibitors) and Huntington's disease (monitoring mutant Huntingtin translation pausing).
Anima’s Translation Control Therapeutics platform is strategically designed for partnering with Pharma. The power of Anima’s approach was solidified with a $1B+ collaboration with Lilly for the discovery and development of translation inhibitors of several targets. Anima’s technology has been further validated by 5 granted patents, 14 peer reviewed publications and 17 scientific collaborations.
Athira Pharma is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Our innovative approach is focused on turning brain degeneration into regeneration, achieved by re-establishing lost connections and restoring lost function.
The Swiss biopharmaceutical company BioVersys focuses on research and development of small molecules which switch off drug resistance against existing antibiotics. With the company’s award-winning TRIC technology (Transcriptional Regulator Inhibitory Compounds) it is possible to restore the efficacy of approved antibiotics. By this, BioVersys addresses the high medical need for new treatments against life-threatening infections that emerged in recent years due to the resistance of bacterial strains against existing antibiotics. BioVersys' compounds will be used in combination with existing antibiotics, thereby renewing efficacy as well as intellectual property for the established drug. The current research focus is Nosocomial Infections (hospital acquired infections) and Tuberculosis. In collaboration with GlaxoSmithKline (GSK) and a consortium of the University of Lille, BioVersys is developing a preclinical candidate for the treatment of multidrug-resistant tuberculosis.
Over the last three decades, the number of newly approved antibiotics has steadily declined. At the same time, resistance against existing drugs has become more and more prevalent. Antibiotic resistance is newly recognized by the WHO as a major public health concern as exemplified by its recently released global report (click HERE for access). BioVersys has a pipeline of promising compounds that address this concern. The company is currently at preclinical stage with proof-of-concept in animals already demonstrated.
Cantargia is a Swedish biotechnology company that specialises in the development of pharmaceuticals for various types of cancer diseases and autoimmune/inflammatory diseases. Our development programme includes the product candidate CAN04, which is currently in phase IIa clinical studies, as well as our discovery project CANxx. The company is listed on OMX Stockholm’s Main List (Small Cap).
Cantargia AB was formed in 2009-2010 with the aim of refining a discovery by Professor Thoas Fioretos and Doctor Marcus Järås of Lund University. Their research showed that leukaemia stem cells express a protein on their surface – IL1RAP – that is not expressed to as great a degree on normal stem cells. Further research by Cantargia showed that this protein is also expressed in solid tumours present in many other types of cancer.
Dyadic International, Inc. is a global biotechnology company based in Jupiter, Florida with a foreign subsidiary, Dyadic Nederland, BV, which maintains a small satellite office in Wageningen, the Netherlands. Over the past two decades, the Company has developed a method for producing commercial quantities of enzymes and other proteins required for the production of industrial enzymes and has successfully licensed this technology to third parties such as Abengoa Bioenergy, BASF, Codexis and others. This technology is based on the Myceliophthora thermophila fungus, which the Company named C1. The C1 technology is a robust and versatile fungal expression system for gene discovery, development, expression and production of enzymes and other proteins.
Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.
Genclis commercializes pre-clinical and cellular models in allergy and autoimmunity to evaluate novel therapeutic, probiotic and nutritional solutions.
Genclis assists commercial partners in:
Evaluating intrinsic allergenicity of pharmaceutical, food and cosmetic ingredients;
Etablishing industrial procedures to control or suppress ingredient’s allergenicity;
Genclis engages in exclusive industrial partnerships for co-development of Transcription Infidelity Assisted Sequential Immunization programs for infectious and immune diseases. Genclis manufactures and commercializes cutting edge reagents for diagnostic and preclinical use.
GeNeuro is a clinical stage pharmaceutical company developing a new approach to the treatment of autoimmune diseases, including multiple sclerosis (MS) and Type 1 Diabetes (T1D) associated with pathogenic proteins expressed by human endogenous retroviruses (HERV), viral genes that account for 8% of human DNA.
This novel approach is the result of 25 years of research on endogenous retroviruses, including 15 within Institut Mérieux and INSERM, before the creation of GeNeuro in 2006. This research has allowed us to uncover and understand the action of a factor potentially causative of multiple sclerosis, the envelope protein (Env), which is produced by a pathogenic member of the human endogenous retrovirus-W family (pHERV-W). The presence of pHERV-W Env in brains of MS patients may be an important driver of the neurodegenerative phenomena characterizing this disease.
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on a proprietary arenavirus platform that is designed to reprogram the body’s immune system.
We are using our ‘‘off-the-shelf’’ technologies, VaxWave®* and TheraT®*, to elicit directly within patients a powerful and durable response of antigen-specific killer T cells and antibodies, thereby activating essential immune defences against infectious diseases and cancers. We believe that our technologies can meaningfully leverage the human immune system for prophylactic and therapeutic purposes by eliciting killer T cell response levels not achieved by other published immunotherapy approaches.
Our platform technology is based on engineering arenaviruses to carry and deliver virus-specific or tumor-specific genes to dendritic cells, which are natural activators of killer T cells, also known as cytotoxic T cells, or CD8+ T cells. We believe we are the first to reengineer arenaviruses for therapeutic purposes. Read more
Our lead infectious disease product candidate, HB-101, is currently in a Phase 2 randomized, double-blinded clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.
Our lead oncology product candidates, HB-201 and HB-202, are in development for the treatment of human papillomavirus-positive cancers. We plan to file an investigational new drug application, or IND, with the U.S. Food and Drug Administration for HB-201 and HB-202 in the first half and second half of 2019, respectively. Read more
We have entered into a strategic partnership with Gilead Sciences, Inc., to accelerate building a pipeline of additional infectious disease product candidates in a cost efficient manner.
IGEM Therapeutics is a UK Immuno-Oncology company developing novel IgE antibodies to treat cancer. IgE has evolved to kill tissue-dwelling multicellular parasites endowing it with several key features that make it ideal for the treatment of solid tumours which also mostly reside in tissue. The epsilon constant region of IgE binds very tightly to its cognate receptor (FcεRI) on the surface of immune effector cells including macrophages, monocytes, basophils and eosinophils. This interaction is up to 10,000 fold greater than the gamma chain of IgG has for its equivalent receptor and this results in the majority of IgE molecules being permanently attached to the surface of immune effector cells. The latter are therefore primed and ready to destroy cells expressing the antigen recognised by the IgE. As a result, IgE is able to permeate tissues more effectively than IgG and stimulate significantly greater levels of both ADCP (antibody-dependent cell-mediated phagocytosis) and ADCC (antibody-dependent cell-mediated cytotoxicity), the two main mechanisms by which immune effector cells can kill tumour cells. IgE also has a significantly longer tissue half life than IgG (2 weeks versus 2 – 3 days) which also suits it for a role in the destruction of solid tumours.
The company’s lead programme targets the folate receptor alpha (FR alpha) and an anti-FR alpha IgE antibody is currently in a phase 1/2a trial to treat ovarian cancer. This is the world’s first IgE therapeutic to enter the clinic.
IGEM is also developing a novel antibody platform technology based on protein and glyco-engineering of the epsilon constant region.
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm.
Innovate is a publicly traded (Nasdaq: INNT) clinical stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases with unmet needs. Our pipeline includes drug candidates for celiac disease, NASH, Crohn's, and ulcerative colitis. Innovate is led by a strong management team with extensive drug development experience and a history of bringing novel therapeutics to market. All global rights to the products, which are backed by more than 150 patents worldwide, are owned by the company.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets. Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells, when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result, Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified CAR-T and TCR-based therapies. Marker is also advancing a number of innovative peptide- and gene-based immuno-therapeutics for the treatment of metastatic solid tumors, including the Folate Receptor Alpha program (TPIV200) for breast and ovarian cancers and the HER2/neu program (TPIV100/110) for breast cancer, currently in Phase II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart™ that can enhance the ability of the immune system to recognize and destroy diseased cells.
Since our creation, the know-how and strong involvement of our people have been essential elements in our development. Our 130 employees, representing more than 20 nationalities, have major holdings in our company’s stock and share a common ambition: to have a real and positive impact on global health.
All of our people are able to become shareholders soon after they start working at MedinCell. In this way, they become real partners, they are strongly involved, and their interests are clearly aligned with those of the Company.
It also helps to guarantee that our people benefit directly from the Company’s success. Moreover, because our people are our main shareholders, we remain independent and stay focused on our mission of Better Medicine For All.
The desire to involve our people in the Company’s success has led to the development of a dynamic entrepreneurial culture at all levels of the business in the service of operational effectiveness.
Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable and troubling side effect of several important cancer treatments.
MP-101 is an orally-active modulator of glutamate signalling in spine and brain. Glutamate signalling has long been a sought-after target for the development of new central nervous system drug candidates. MP-101 is a particularly well-suited candidate, with outstanding pharmaceutic properties; it is a small molecule, obtained by a straight-forward chemical manufacturing process. It is also orally active in a wide range of rodent models of central nervous system disorders, such as depression, cognition, or neuropathic pain.
MP-101 is a patent-pending non-racemic mixture of the left-handed and right-handed versions (the "enantiomers") of dimiracetam. It is not a one-to-one mixture (a "racemate"), but a ratio that has been chosen because it is - unexpectedly - considerably more potent pharmacologically than the racemate. While the one-to-one mixture has long been known to be superior to either of the two single-handed enantiomers alone, Metys Pharmaceuticals has discovered that certain mixtures of dimiracetam enantiomers are far more potent still.
Metys Pharmaceuticals has licensed the world-wide exclusive rights to racemic dimiracetam from Neurotune AG, including the entire dossier of regulatory studies supporting clinical trials of racemic dimiracetam. Metys Pharmaceuticals now aims to use these pharmacological, toxicological and clinical data obtained with racemic dimiracetam to support the future clinical trials of MP-101.
Founded in 2015, Omnix Medical is a biopharmaceutical company developing an arsenal of novel antibiotic agents for the treatment of infections involving drug resistant bacteria. Omnix’s agents are based on natural antimicrobial peptides, genetically engineered to be compatible for therapeutic use.
Omnix focuses on ESKAPE pathogens: K. pneumonia species, A. baumannii, P. aeruginosa and Enterobacter species. While these bacteria are the most serious and urgent threat to public health, the drugs intended to fight them are becoming ineffective as they rapidly develop antibiotic resistance. Our peptides are being developed for systemic administration in serious hospital acquired infections.
Omnix is addressing an enormous and rapidly growing market opportunity, represented by millions worldwide, who suffer from infections associated with resistant bacteria. Researchers estimate that by the year 2050, drug-resistant bacteria will cause more than 10 million deaths and cost the global economy an excess of $100 trillion annually.
Omnix Medical’s agents are eligible for FDA QIDP-breakthrough therapy status, which allows for a fast development pathway and an additional 5 years of exclusivity.
Omnix’s technology can tilt the odds in the battle against resistant bacteria and improve the lives of many people worldwide.
Oryzon is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics.
From its founding in 2000 through 2008, the company focused its efforts in growing a genomics diagnostics business model, providing genomics services to the pharmaceutical industry in Europe. In 2008, with the acquisition of Crystax Pharmaceuticals, we started our drug discovery programs in oncology and neurodegenerative diseases. Our business model is to develop our proprietary drug candidates through clinical phase II, at which point it is decided on a case-by-case basis to either keep the development in-house or to partner or outlicense the compound for late stage development and commercialization.
Oryzon is listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). In the period 2015-2016, the company raised €32M, with additional Pipes in 2017 (€18.2M) and 2018 (€13M) where the company incorporated specialized investors from US and Europe.
The company has a broad and growing portfolio, with two compounds in clinical trials, iadademstat (ORY-1001), a highly potent and selective LSD1 inhibitor that has been granted orphan-drug status by EMA, in Phase IIa in oncology, and vafidemstat (ORY-2001), a dual LSD1/MAO-B inhibitor for the treatment of multiple sclerosis, Alzheimer’s disease and other neurodegenerative diseases, in Phase IIa, as well as another compound in preclinical development, ORY-3001, a selective LSD1 inhibitor for the treatment of non-oncological diseases, and additional programs in other cancer indications.
From 2014 to 2017 the company had a collaboration with Roche relating to our lead oncology program, iadademstat, and received +$23M. This asset is now being developed by Oryzon. The company has also obtained competitive US and European grants in the amount of €8M to support the development of vafidemstat since the start of our CNS research.
The company has a seasoned executive management with vast experience in the industry.
Perseo pharma takes its name from Perseus, the hero of Greek mythology who, by wearing the Cap of Invisibility, was able to slay the Gorgon Medusa whose gaze was turning onlookers into stone. Perseo pharma’s therapeutic enzymes, with their stealth coating, are able to invisibly reach their targets so as to slay the disease. Over the past 30 years and the first development of biologics, 30 therapeutic enzymes have been approved by EMA and FDA (1/4 of all approved biologics). Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). However, existing therapeutic enzymes exhibit both efficacy issues (lack of systemic stability, low residence time) and toxicity issues (up to 80% anti-drug reactions, immunogenicity).
Primex Pharmaceuticals is a leading global innovative anaesthesia company, expanding in paediatric pharmaceuticals.
Primex brings a broad portfolio of anaesthesia products helping patients undergo a wide range of medical procedures, including a novel, oral solution for paediatric sedation now approved in several markets in the European Union.
Primex Pharmaceuticals will continue to identify and bring to the market new medications that complete the Triad of Anaesthesia. In addition, the Group includes a complimentary range of local anaesthetics and dental products under the OGNA® brand.
Primex Pharmaceuticals’ global partner network operates in over 40 countries. The company is headquartered in Switzerland; all Primex products are manufactured in Europe. Primex Pharmaceuticals has proven underlying business operations and historical strong revenue growth.
STALICLA is a mission-driven biotech, with a unique patient centric vision, that is poised to become a disruptive industry challenger and future global leader in personalized treatment options for patients with Autism Spectrum Disorder (ASD). At STALICLA, we have developed an innovative algorithm platform that uses robust sets of clinical signs and symptoms with big data analytics to identify subgroups of ASD patients. By identifying these subgroups, we aim to offer repurposed drugs that provide more effective, personalized treatment options.
The company was founded in Geneva, Switzerland in May 2017 by today’s CEO Lynn Durham, a biotech entrepreneur with a lifelong involvement with the autism community. STALICLA has established a research partnership with the Greenwood Genetic Center, South Carolina, USA, a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
TOLREMO therapeutics AG (“TOLREMO”) is a Swiss biotechnology company that was spun out of ETH Zurich in 2017. Based on cutting-edge science and guided by pioneering real-world medicine, TOLREMO created a broad cancer drug resistance platform that provides a unique entry point into a major clinical problem. In two parallel R&D programs the company develops resistance-breaking add-on therapies that extend the therapeutic benefit of oncogene-targeting cancer drugs (Adaptive Drug Resistance Program) and anti-angiogenic cancer drugs (Hypoxia-Driven Drug Resistance Program). TOLREMO’s unique drug resistance platform has the potential to catalyze a new wave of potent resistance-breaking molecules that will meaningfully extend the lives of patients suffering from cancer.
TOLREMO is headquartered on the ETH Hönggerberg campus in Zurich, Switzerland, where the company is part of a dynamic scientific and entrepreneurial community composed of world-leading academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. TOLREMO enjoys broad access to state-of-the art ETH infrastructure including laboratory space and an industry standard robotic screening facility.
Versameb AG is a regenerative medicine research and development company. Regenerative medicine is one of the largest health challenges and unmet medical needs affecting a majority of the world‘s aging population. Our mission is to design novel technologies for local growth factor delivery with a dramatically prolonged biological activity. We are aiming to provide definitive, simple and highly valuable solutions for restoring tissue functions, notably joint, bone, muscle and wound healing, all significant unmet medical needs. Our expertise, knowledge and intellectual property will allow us to deliver game-changing solutions in this field.